Prescription Medicines
Valtrio tab 10/160/10mg
- Product Category
- Antihypertension & dyslipidemia treatment
- Active Ingredients
- Amlodipine, valsartan, rosuvastatin
- Appearance
- Pink, egg-shaped, biconvex film-coated tablets
- Reimbursement Code
- 648104550
01 / 02
1. Ingredient content
- Active ingredient: Amlodipine besylate (USP) ---------- 13.87mg (10mg as amlodipine)
Valsartan (USP) -------------------- 160mg
Rosuvastatin Calcium (EP) ------------ 10.40mg (10mg as rosuvastatin)
- Additives: Anhydrous calcium hydrogen phosphate, microcrystalline cellulose, magnesium stearate, Opadry pink (03B640002), low-substituted hydroxypropyl cellulose, colloidal silicon oxide, crospovidone
2. Effectiveness
This drug is only used in patients who need to take amlodipine/valsartan combination and rosuvastatin simultaneously.
▷ Amlodipine/valsartan combination drug
Essential hypertension whose blood pressure is not adequately controlled with amlodipine or valsartan monotherapy
▷ Rosuvastatin
1. Primary hypercholesterolemia (type IIa including heterozygous familial hypercholesterolemia), combined dyslipidemia (type IIb)
: Dietary supplement in cases that cannot be controlled through diet and exercise
2. Adjuvant to diet or other lipid-lowering therapy (e.g. LDL apheresis) for homozygous familial hypercholesterolemia
3. Delays the progression of atherosclerosis by lowering total cholesterol and LDL-cholesterol to target levels in patients with hypercholesterolemia.
4. Dietary supplement for patients with primary dysbetalipoproteinemia (type III)
5. Reduces risk for cardiovascular disease
: Patients with no clinical evidence of coronary heart disease, but who are men over 50 years of age and women over 60 years of age, have a high sensitive C-reactive protein (hsCRP) of 2 mg/L or more, and have at least one additional cardiovascular disease risk factor (e.g. high blood pressure, low HDL-cholesterol level, smoking, or family history of premature coronary heart disease, etc.)
- Reduced risk of stroke
- Reduced risk of myocardial infarction
- Reduced risk of arterial revascularization
3. Dosage and dosage
Take this medicine 1 tablet once a day with water. If possible, it is recommended to take it at the same time every day (e.g. before breakfast).
This drug is administered only to adults, and the dosage should be individualized for each patient based on the effectiveness and tolerability of the amlodipine/valsartan combination and rosuvastatin.
For patients who are taking a combination of amlodipine/valsartan and rosuvastatin as a single drug, they can switch to this drug (a combination drug with the same content of each active ingredient) for convenience of administration.
▷ Amlodipine/valsartan combination drug
It is recommended to adjust the dose of the individual ingredients (amlodipine or valsartan) before administering the amlodipine/valsartan combination medication. However, if blood pressure is not controlled with monotherapy with each ingredient as follows, switching directly to the amlodipine/valsartan combination medication can be considered.
ㆍ5/80 mg: Administered to patients whose blood pressure is not adequately controlled with monotherapy with 5 mg of amlodipine or 80 mg of valsartan.
ㆍ5/160 milligrams: Administered to patients whose blood pressure is not adequately controlled with monotherapy with 5 milligrams of amlodipine or 160 milligrams of valsartan.
ㆍ10/160 milligram: Administer to patients whose blood pressure is not properly controlled with 10 milligrams of amlodipine or 160 milligrams of valsartan alone or with 5/160 milligrams.
Patients with renal impairment: No dosage adjustment is necessary for patients with mild or moderate renal impairment (creatinine clearance of 10 mL/min or more), but patients with severe renal impairment (creatinine clearance of less than 10 mL/min) and dialysis patients do not receive amlodipine/valsartan combination medication. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended.
Patients with hepatic impairment: For patients with mild and moderate hepatic impairment, the daily dose of valsartan should not exceed 80 mg. Amlodipine/valsartan combination medication should not be administered to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or bile secretion arrest.
Elderly people over 65 years of age: Caution should be exercised when increasing the dose.
▷ Rosuvastatin
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbeta-lipoproteinemia (type III), and homozygous familial hypercholesterolemia.
Patients before and while receiving rosuvastatin should follow a standard cholesterol-lowering diet and continue this during the treatment period. Rosuvastatin can be administered at any time of the day, regardless of meals. The initial dose is 5 milligrams once a day, and if further LDL-cholesterol level reduction is required, the maintenance dose can be adjusted. The maintenance dose is 10 milligrams once a day, and most patients are adjusted to this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more depending on the LDL-cholesterol level, treatment goals, and patient response, and the dose can be increased up to 20 milligrams per day.
2. Elderly: No dosage adjustment is necessary.
3. Patients with renal failure: For patients with mild to moderate renal failure, there is no need to adjust the dose. Do not administer to patients with severe renal failure. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal failure.
4. Patients with liver failure: There was no increase in systemic exposure to rosuvastatin in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score exceeding 9. Rosuvastatin is not administered to patients with active liver disease.
5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of doses of 40 milligrams is contraindicated.
6. Patients prone to myopathy: The recommended initial dose for patients prone to myopathy is 5 milligrams. In some of these patients, administration of rosuvastatin at a dose of 40 mg is contraindicated.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin system are administered to pregnant women in the second or third trimester of pregnancy, they can cause damage and even death to the fetus and newborn. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately. (Refer to ‘2. Do not administer to the following patients’ and ‘7. Administration to pregnant and lactating women’)
2. Do not administer to the following patients
1) Patients with hypersensitivity to the components or dihydropyridine derivatives of this drug
2) Pregnant women, women who may be pregnant, and lactating women
3) Patients with severe liver dysfunction, biliary cirrhosis, biliary obstruction, and bile secretion arrest
4) Patients with active liver disease, including persistent serum transaminase elevations of unknown cause or serum transaminase elevations exceeding 3 times the upper limit of normal.
5) Patients with severe renal impairment (creatinine clearance less than 30mL/min)
6) Combination use with aliskiren-containing preparations in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2)
7) Patients with hereditary angioedema or a history of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
8) Patients with primary hyperaldosteronism (This drug is not administered to patients with primary hyperaldosteronism because the renin-angiotensin-aldosterone system is not activated.)
9) Patients with severe aortic stenosis
10) Shock patients
11) Patients with myopathy
12) Patients taking cyclosporine concurrently
13) Rosuvastatin administration at a dose of 40 mg is contraindicated in patients prone to myopathy/rhabdomyolysis. These factors are as follows.
- Moderate renal impairment (creatinine clearance < 60ml/min)
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA converting enzyme or fibrate drugs
- alcoholism
- Situations in which plasma concentrations may increase
- Asian patient
- Concomitant administration of fibrate-based drugs
3. Administer with caution to the following patients:
1) Patients with sodium and/or fluid deficiency
In a placebo-controlled clinical trial, excessive hypotension was observed in 0.4% of patients with uncomplicated hypertension who received the amlodipine/valsartan combination. In patients with an activated renin-angiotensin system who are taking angiotensin receptor antagonists (ARB antagonists) (e.g., volume and/or sodium depleted patients taking high doses of diuretics), symptomatic hypotension may occur. It is recommended that these conditions be corrected prior to administration of this drug or that close medical observation be observed upon initiation of treatment.
If low blood pressure occurs when taking this medicine, have the patient lie down and, if necessary, inject saline solution intravenously. Treatment can be continued after blood pressure stabilizes.
2) Patients with hyperkalemia
Caution should be exercised when coadministering this drug with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other drugs that may increase potassium levels (e.g. heparin), and potassium levels should be monitored frequently.
3) Patients with renal artery stenosis
This drug may increase blood urea and serum creatinine in patients with bilateral or unilateral renal artery stenosis caused by valsartan or in patients with short stature and stenosis, so monitoring is recommended for safety.
4) Kidney transplant patient
There are no data to demonstrate the safe use of this drug in patients who have recently undergone a kidney transplant.
5) Angioedema
Angioedema (including swelling of the larynx and glottis) causing airway obstruction and/or swelling of the face, lips, and tongue has been reported in patients receiving valsartan. Some of these patients had experienced angioedema caused by other medications, such as ACE inhibitors. If angioedema occurs during administration of this drug, administration should be discontinued immediately and should not be re-administered.
6) Patients after heart failure or myocardial infarction
In general, caution is advised when using calcium channel antagonists such as amlodipine in patients with severe congestive heart failure (NYHA class III or IV). In a placebo-controlled trial (PRIASE-2) in patients with NYHA stage III or IV heart failure of nonischemic origin, amlodipine was reported to be associated with an increase in pulmonary edema despite clearly reducing exacerbations of heart failure compared to placebo.
In patients whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system (e.g., severe heart failure), administration of angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
7) Patients with acute myocardial infarction
An increase in the frequency, duration, or severity of angina pectoris or acute myocardial infarction has been rarely reported in patients (particularly those with severe obstructive coronary artery disease) who started taking or increased the dose of a calcium channel blocker (e.g., amlodipine).
8) Patients with aortic and mitral valve stenosis and obstructive hypertrophic cardiomyopathy
As with all other vasodilators, special caution is required when administering amlodipine to patients with aortic or mitral atresia or obstructive hypertrophic cardiomyopathy.
9) Patients with severe muscle atony or ocular muscle atony
Cases of recurrence have been reported when the same or different types of statin drugs were administered.
10) Dual blockade of renin-angiotensin-aldosterone system (RAAS)
Concomitant use with other drugs that affect the renin-angiotensin-aldosterone system (RAAS), such as angiotensin receptor blockers (ARBs), ACE inhibitors, or aliskiren, including valsartan, is not recommended.
11) Patients with mild to moderate hepatic impairment (In patients with mild to moderate hepatic impairment, it is recommended that the daily dose of valsartan among the ingredients of this drug do not exceed 80 mg.)
12) Like other HMG-CoA reductase inhibitors, rosuvastatin should be administered with caution to patients who consume excessive alcohol or have a history of liver disease. It is recommended that liver enzyme tests be performed repeatedly as clinically necessary before and after starting rosuvastatin treatment. Patients with hypercholesterolemia secondary to hypothyroidism or nephrotic syndrome must treat the causative disease before administering rosuvastatin.
13) As with other HMG-CoA reductase inhibitors, effects on skeletal muscle, such as myalgia and myopathy, and rarely rhabdomyolysis, have been reported in patients receiving rosuvastatin. Immune-mediated necrotizing myopathy has been reported in patients taking or discontinuing statins, including rosuvastatin. Immune-mediated myopathy is clinically characterized by weakened proximal muscles and increased CK (creatine kinase) in the blood, and the symptoms persist even after discontinuation of treatment.
· As with other HMG-CoA reductase inhibitors, the risks and benefits of treatment should be considered in the following patients with factors predisposing to myopathy/rhabdomyolysis, and clinical monitoring is recommended. Treatment should not be started if the CK (creatine kinase) value is significantly increased from the baseline level (more than 5 times the upper limit of normal) before treatment.
- Patients with renal impairment
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA reductase inhibitors or fibrates.
- alcohol abuse
- Seniors over 70 years old
- Situations in which plasma concentrations may increase
- Concomitant administration of fibrate-based drugs
· During treatment, unexplained muscle pain, muscle weakness or cramps should be reported immediately, especially if associated with malaise or fever. In these patients, the CK level should be measured, and if the CK level is significantly elevated (more than 5 times the upper limit of normal) or if the muscle symptoms are severe and cause daily discomfort even if the CK level increases below 5 times the upper limit of normal, administration of this drug should be discontinued. Once symptoms resolve and CK levels return to normal, consideration should be given to restarting rosuvastatin or another HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels is not necessary in asymptomatic patients.
· Because it may make interpretation of the measurement results difficult, do not measure CK after intense exercise or when there are other causes that may increase the CK value. If the CK value increases significantly from baseline (more than 5 times the upper limit of normal), a confirmatory test should be performed within 5 to 7 days. Even when repeating the test, this drug should not be administered if the baseline CK value increases more than 5 times the upper limit of normal.
14) This drug should be discontinued in acute severe conditions that suggest worsening of myopathy or renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, wounds, severe metabolic/endocrine/electrolyte diseases, uncontrolled epileptic seizures).
15) In clinical trials, there was no evidence of increased effects on skeletal muscle in the small number of patients who received rosuvastatin in combination with other drugs. However, in the case of other HMG-CoA reductase inhibitors, the frequency of myositis and myopathy increased in patients receiving concurrent treatment with fibric acid derivatives (including gemfibrozil), cyclosporine, nicotinic acid, azole antifungals, protease inhibitors, and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when combined with HMG-CoA reductase inhibitors. Therefore, the combined use of this drug and gemfibrozil is not recommended. When administering this drug in combination with fibrates or niacin, the benefits and risks should be carefully evaluated. A dose of 40 milligrams of rosuvastatin is contraindicated when coadministered with fibrate-based drugs.
16) In patients taking high doses of rosuvastatin, especially 40 mg, proteinuria, mostly of tubular origin, detected by dipstick test was observed. This is usually transient and is not a predictor of acute or progressive renal failure. Renal function tests should be considered during the follow-up period for patients receiving 40 mg.
17) According to a pharmacokinetic study of rosuvastatin, an increase in systemic exposure (median AUC and Cmax approximately 2-fold increase) was observed in Asians compared to Caucasians, so this should be taken into consideration when determining dosage for Asians.
4. Adverse reactions
1) Amlodipine/valsartan/rosuvastatin combination drug
The safety of this drug was evaluated in a clinical trial in which 175 patients with both hypertension and dyslipidemia were administered a combination of amlodipine/valsartan and rosuvastatin (58 patients), a combination of amlodipine/valsartan (58 patients), or a combination of valsartan and rosuvastatin (59 patients) for 8 weeks.
The adverse reactions reported in the amlodipine/valsartan combination and rosuvastatin combination group (58 patients), regardless of causal relationship with the test drug, are as follows.
[See Table 1]
2) Information collected from amlodipine/valsartan combination medication
(1) The safety of the amlodipine/valsartan combination was evaluated from 5 controlled clinical trials in which 5,175 patients participated, 2,613 of whom received amlodipine and valsartan in combination.
Adverse reactions were classified according to frequency of occurrence into very common (≥ 1/10), common (≥ 1/100, <1/10), uncommon (≥ 1/1,000, <1/100), rare (≥ 1/10,000, <1/1,000), and very rare (<1/10,000), including independent reports. In the same frequency group, adverse reactions were organized in decreasing order of seriousness.
[See Table 2]
(2) Additional information on combined use
In a double-blind, drug- or placebo-controlled clinical trial, the incidence of peripheral edema was statistically lower in the combination treatment group (5.8%) compared to the amlodipine treatment group alone (9%).
(3) Domestic post-marketing survey results
① As a result of a usage results survey conducted on 859 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 5.12% (44 people, 56 cases) regardless of causal relationship.
The incidence of adverse drug reactions for which a causal relationship with the amlodipine/valsartan combination cannot be ruled out was 1.75% (15 people, 19 cases), headache 0.47% (4 people, 4 cases), dizziness 0.35% (3 people, 3 cases), itching 0.35% (3 people, 3 cases), peripheral edema 0.23% (2 people, 2 cases), Low blood pressure was observed in 0.23% (2 people, 2 cases), and edema, chest pain, pain, cough, and enuresis were observed in 1 case each.
No serious adverse events were reported regardless of causal relationship with the amlodipine/valsartan combination. As unexpected adverse events, a total of 9 cases were reported: chest discomfort 0.23% (2 people, 2 cases), pain, abdominal discomfort, reflux esophagitis, neck pain, hypercholesterolemia, hypoglycemia, and enuresis. A total of 2 unexpected adverse drug reactions occurred, 1 case of pain and 1 case of enuresis.
② As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect report data for the amlodipine/valsartan combination drug with the adverse event report data reported for all drugs approved for domestic marketing at the end of the re-examination, the newly identified adverse events that were statistically significantly more reported in the amlodipine/valsartan combination drug compared to the adverse cases reported in all other drugs are as follows. However, this result does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
· Systemic abnormalities: chest pain, weight gain
· Musculoskeletal system: joint pain, skeletal pain, rhabdomyolysis
· Oral: Gum hyperplasia
· Gastrointestinal system: gastritis
· Mental disorder: nervousness
· Nervous system: decreased sensation
· Skin and subcutaneous tissue abnormalities: Stevens-Johnson syndrome
3) Information collected from valsartan/rosuvastatin combination medication
※ Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 698 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 14.90% (104/698 people, 137 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
[See Table 3]
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
[See Table 4]
4) Information collected from amlodipine/rosuvastatin combination medication
(1) Domestic post-marketing surveillance results following re-examination
As a result of a post-marketing survey conducted on 654 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 26.30% (172/654 people, 237 cases) regardless of causal relationship. Among these, no serious adverse drug reactions for which a causal relationship cannot be ruled out were reported, and unexpected adverse drug reactions are listed in the table below according to their frequency of occurrence.
[See Table 5]
5) Additional information on individual active ingredients
Although not observed in clinical trials and post-marketing experience with this drug, adverse reactions previously reported for each component may occur.
(1) Amlodipine
Regardless of the causal relationship with the drug, adverse reactions reported in amlodipine clinical trials are listed in <Table 3>.
[See Table 6]
Gynecomastia has been rarely reported during post-marketing use, but the causal relationship with amlodipine is not clear. Additionally, jaundice and elevated liver enzymes (most often consistent with biliary dysfunction or hepatitis) have been reported to be associated with amlodipine administration, and some cases were severe enough to require hospitalization. Leukopenia, thrombocytopenia, confusion, exfoliative dermatitis, Stevenson-Johnson syndrome, photosensitivity reaction, and toxic epidermal necrolysis have been reported (frequency unknown).
For additional safety information, refer to the amlodipine single-substance labeling.
(2) Valsartan
[See Table 7]
Regardless of the causal relationship with the drug, the following symptoms were reported during clinical trials: insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, and viral infection.
Intestinal angioedema has been reported during post-marketing use (very rarely).
For additional safety information, refer to the valsartan single-substance labeling.
(3) Rosuvastatin
① Reported adverse reactions were generally mild and transient. Less than 4% of patients in the rosuvastatin treatment group discontinued the study due to adverse reactions.
The frequency of adverse reactions was classified as follows: common (>1/100, <1/10); Uncommon (>1/1,000, <1/100); Rare (>1/10,000, <1/1,000); Very rare (<1/10,000). Not known (cannot be estimated from available data)
As with other HMG-CoA reductase inhibitors, adverse reactions tended to increase as the dose increased.
② Effect on kidneys: Proteinuria, mostly of tubular origin, detected by dipstick test, was observed. The phenomenon of conversion of urine protein from negative or very small amounts to ++ or higher occurred in less than 1% of cases at 10 or 20 milligrams and in about 3% of cases at 40 milligrams. A slight increase in urine protein from negative or very small amounts to + was also observed at the 20 mg dose. Proteinuria decreased or disappeared spontaneously during treatment in most cases and is not a predictor of acute or progressive renal failure. Hematuria was observed in patients and clinical trial data administered rosuvastatin, but the frequency of occurrence was low.
③ Effects on the musculoskeletal system: Effects on the musculoskeletal system with or without acute renal failure (e.g., myalgia, myopathy (including myositis), rarely rhabdomyolysis, etc.) have been reported in patients treated with all doses of rosuvastatin (especially 20 mg or more). In the patient group receiving rosuvastatin, creatinine kinase (CK) levels increased in a dose-dependent manner. In most cases, it was mild, asymptomatic, and transient. If creatinine kinase (CK) levels increase significantly (more than 5 times the upper normal limit), treatment should be temporarily discontinued.
④ Effect on the liver: As with other HMG-CoA reductase inhibitors, transaminase levels increased in a dose-dependent manner in a small number of patients receiving rosuvastatin. In most cases, it was mild, asymptomatic, and transient.
⑤ Overseas post-marketing experience
In addition to the above adverse reactions, the following adverse reactions were reported during post-marketing surveillance.
- Nervous system: Very rare polyneuropathy, amnesia, peripheral neuropathy (frequency unknown)
- Respiratory system and chest: cough, difficulty breathing (frequency unknown)
- Gastrointestinal system: Diarrhea (frequency unknown)
- Hematological disorders: Thrombocytopenia (frequency unknown)
- Hepatobiliary system: very rare, jaundice, hepatitis, rarely increased transaminases
- Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (frequency unknown), drug reaction syndrome with increased eosinophils and systemic symptoms (DRESS) (frequency unknown)
- Musculoskeletal system: Rarely lupus-like syndrome, muscle rupture, very rarely arthralgia, immune-mediated necrotizing myopathy (frequency unknown)
- Kidney: Very rare hematuria
- Other: Edema (frequency unknown)
The following adverse reactions have been reported in relation to some statin drugs.
- Mental nervous system: depression, sleep disorders (including insomnia and nightmares) (frequency unknown)
- Respiratory system: Exceptional cases such as interstitial lung disease, especially during long-term administration
- Urogenital system: sexual dysfunction, gynecomastia (frequency unknown)
- Hepatobiliary system: Fatal and non-fatal liver failure
There have been rare reports of post-marketing cognitive impairment associated with statin use. (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) Such cognitive impairment has been reported with all statin drugs. These reports are generally not serious and reversible after discontinuation of drug use, but there is variation in the time of symptom onset (1 day to several years) and symptom improvement (median 3 weeks). The induction or worsening of severe muscle atony or ocular muscle atony has been reported with the administration of statin drugs.
⑥ Domestic post-marketing survey results
As a result of a usage outcome survey conducted on 3,081 people over 6 years for re-examination in Korea, regardless of causal relationship, the occurrence rate of adverse events was 10.06% (310 people, 415 cases), mainly headache 0.78% (24 people, 24 cases), dizziness 0.75% (23 people, 23 cases), and ALT increase 0.58% (18 people, 18 cases). 18 cases), chest pain, cough, and muscle pain were reported in 0.49% (15 people, 15 cases) each, and of these, 2.92% (90 people, 106 cases) of adverse drug reactions for which a causal relationship with rosuvastatin could not be ruled out.
The most common adverse drug reactions reported were ALT increase at 0.55% (17 people, 17 cases), muscle pain at 0.42% (13 people, 13 cases), headache at 0.39% (12 people, 12 cases), CK increase at 0.29% (9 people, 9 cases), dizziness at 0.26% (8 people, 8 cases), constipation, and AST increase. 0.16% (5 people, 5 cases), asthenia and joint pain each at 0.13% (4 people, 4 cases), fatigue and numbness at 0.10% each (3 people, 3 cases), paresthesia, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, itching, liver function test abnormalities at 0.06% each (2 people, 2 cases), syncope, systemic pain, Muscle cramps, gout, and erectile dysfunction each occurred in 0.03% (1 person, 1 case). Among these, muscle pain and joint pain in one patient were serious adverse drug reactions, and unexpected adverse drug reactions that did not appear before marketing included joint pain in 0.13% (4 patients, 4 cases), fatigue and numbness in 0.10% (3 patients, 3 cases), paresthesia, chest discomfort, loss of appetite, abdominal distension, and liver function test abnormalities in 0.06% (2 patients, 2 cases) respectively, syncope, and General pain, muscle cramps, gout, and erectile dysfunction occurred in 0.03% (1 person, 1 case) each, and one case of joint pain was reported as a serious and unexpected adverse drug reaction.
There were 98 adverse events voluntarily reported during the re-examination period, of which 2 cases of acute renal failure and 1 case each of oliguria, thrombocytopenia, and increased blood creatinine were reported as serious and unexpected adverse drug reactions.
5. General precautions
1) Be careful when driving and operating machines
Clinical trials have not been conducted on the effects on driving and using machinery. It should be taken into account that dizziness and fatigue may occur intermittently when driving or using machinery. As with other antihypertensive drugs, take special care when driving or operating machinery.
2) Amlodipine
(1) Administration to patients with heart failure: In the long-term, placebo-controlled trial (PRAISE-2) of amlodipine in patients with NYHA class III and IV heart failure without ischemic etiology, amlodipine was associated with an increase in reports of pulmonary edema despite no significant difference in the worsening rate of heart failure compared with placebo.
(2) Administration to patients with impaired liver function: Like all calcium antagonists, the half-life of amlodipine is prolonged in patients with impaired liver function, and the recommended dosage for these patients has not been established. Therefore, administer with caution to these patients.
(3) Because the plasma concentration half-life is long, a gradual blood pressure lowering effect appears even after discontinuation of administration, so when administering other antihypertensive drugs after discontinuation of administration, pay attention to the dosage and administration interval and administer carefully while observing the patient's condition.
(4) Since the effect appears slowly, it cannot be expected to be effective in unstable angina pectoris that requires emergency treatment.
3) Valsartan
(1) Administration of valsartan may cause a rapid temporary drop in blood pressure (accompanied by fainting and loss of consciousness, etc.) after the first administration, so in such cases, discontinue administration and take appropriate measures. In addition, especially in the following patients, administration should be started at a low dose and the dose increased slowly while carefully observing the patient's condition.
① Patients undergoing hemodialysis
② Patients taking diuretics (especially in patients with severe sodium deficiency or volume deficiency, caution may occur in rare cases of symptomatic hypotension).
③ Patients undergoing strict salt restriction
(2) In patients with severe sodium depletion or body fluid depletion due to taking high doses of diuretics, hypotension may rarely occur in the early stages of valsartan administration. Before valsartan administration, this depletion of sodium and body fluid must be corrected by methods such as reducing the diuretic dose. If low blood pressure occurs, have the patient lie down in an upright position and, if necessary, inject physiological saline solution by drip. Continue drug administration after blood pressure stabilizes.
(3) Patients with renal artery stenosis: Short-term administration of valsartan to 12 patients with renovascular hypertension accompanied by secondary unilateral renal artery stenosis did not induce significant changes in renal hemodynamics, serum creatinine, and BUN. However, when other drugs that affect the renin-angiotensin-aldosterone system are administered to patients with bilateral or unilateral renal artery stenosis, blood urea and serum creatinine may increase, so monitoring is recommended for safety reasons. In patients with bilateral or unilateral renal artery stenosis, there is a risk of rapid deterioration of renal function due to decreased renal blood flow and decreased glomerular filtration pressure, so administration should be avoided except in cases where treatment is deemed unavoidable.
(4) It is desirable that the daily dose of valsartan for patients with mild to moderate hepatic impairment does not exceed 80 mg. Valsartan is mostly excreted in bile as an unchanged form and has a low clearance rate in patients with biliary obstruction, so it is not used in these patients. It has been reported that when valsartan is administered to patients with mild to moderate hepatic impairment, the plasma concentration increases approximately twice that of healthy adults.
(5) Patients receiving valsartan after heart failure or myocardial infarction mainly experience a decrease in blood pressure, but there is no need to discontinue treatment due to persistent symptoms of hypotension. Caution should be exercised when initiating treatment in patients with heart failure or after a myocardial infarction.
As a result of inhibition of the renin-angiotensin-aldosterone system, changes in renal function are expected in susceptible patients. Treatment with ACE inhibitors and angiotensin II receptor antagonists in patients with severe heart failure whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system has been associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Similar results have been reported with valsartan. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
Triple therapy of ACE inhibitors, beta-blockers, and valsartan is not recommended in patients with heart failure. This is because simultaneous administration of beta-blockers and ACE inhibitors increases morbidity and mortality due to heart failure.
Increases in BUN, creatinine, and potassium levels have been observed in some heart failure patients. This phenomenon is mainly mild and temporary, and is likely to occur in patients with pre-existing renal damage. Dosage reduction and discontinuation of valsartan and/or diuretics should be considered.
(6) In patients with hyperkalemia, administration should be avoided except in cases where treatment is deemed unavoidable as there is a risk of worsening hyperkalemia. Additionally, patients who are prone to elevated serum potassium levels due to kidney dysfunction, diabetes, etc., may develop hyperkalemia, so pay attention to serum potassium levels.
(7) There is no experience of use in patients who recently underwent kidney transplantation.
(8) Intestinal angioedema has been reported in patients receiving angiotensin II receptor antagonists. These patients presented with abdominal pain, nausea, vomiting, and diarrhea. Symptoms resolved after discontinuation of angiotensin II receptor antagonist. If intestinal angioedema is diagnosed, treatment should be discontinued and appropriate monitoring should be conducted until symptoms completely resolve.
4) Rosuvastatin
(1) Interstitial lung disease: Unusual cases such as interstitial lung disease have been reported with some statin drugs, especially during long-term administration. Presenting symptoms may include difficulty breathing, cough without phlegm, and general deterioration in health (fatigue, weight loss, and fever). If a patient is suspected of developing interstitial lung disease, statin drug treatment should be discontinued.
(2) Post-marketing cases of fatal and non-fatal liver failure have been rarely reported in patients taking statin drugs, including rosuvastatin. If severe liver damage and/or hyperbilirubinemia or jaundice with clinical symptoms occurs while taking this drug, treatment should be discontinued immediately. Do not re-administer this drug if no other etiology is found.
(3) Increases in HbA1c and fasting blood sugar levels were reported when administering HMG-CoA reductase inhibitors, including rosuvastatin.
(4) Diabetes: Some evidence suggests that hyperglycemia, which requires appropriate diabetes treatment, may occur in some patients at high risk of developing diabetes in the future. However, the vascular risk reduction effect of statins exceeds these risks and therefore cannot be a reason to discontinue statin treatment. Patients at risk (fasting blood sugar 5.6-6.9 mmol/L, BMI > 30kg/m2, elevated triglyceride level, hypertension) should undergo clinical and laboratory monitoring according to treatment guidelines.
In the JUPITER study, the total incidence of diabetes reported in patients with fasting blood sugar levels of 5.6 to 6.9 mmol/L was 2.8% in the rosuvastatin group and 2.3% in the placebo group.
(5) Genetic polymorphism: SLCO1B1(OATP1B1) c compared to SLCO1B1 c.521TT and ABCG2 c.421CC. The genotype of 521CC or ABCG2 (BCRP) c.421AA has been reported to be associated with increased exposure (AUC) of rosuvastatin. Although the safety and effectiveness of rosuvastatin according to genetic polymorphisms have not been established, the dose needs to be adjusted according to the patient's treatment response and tolerance.
(6) Immune-mediated necrotizing myopathy: Immune-mediated necrotizing myopathy, an autoimmune myopathy related to statin use, has been reported. Immune-mediated necrotizing myopathy manifests as proximal muscle weakness and increases in blood CPK, and the symptoms persist even after discontinuation of statin administration. Additionally, muscle biopsy shows necrotizing myopathy without significant infection, and symptoms improve upon administration of immunosuppressants.
(7) Severe skin adverse reactions: Severe skin adverse reactions that can be life-threatening or fatal, such as Stevens-Johnson syndrome (SJS) and drug reaction syndrome with increased eosinophilia and systemic symptoms (DRESS), have been reported with rosuvastatin. When prescribing, patients should be advised of symptoms and signs of severe skin reactions and monitored closely. If symptoms and signs suggestive of these skin reactions occur, this medication should be discontinued immediately and alternative treatment options should be considered.
If a patient develops a severe reaction such as Stevens-Johnson syndrome or drug reaction syndrome with eosinophilia and systemic symptoms due to the use of this drug, treatment with this drug should not be resumed at any time.
(8) Severe muscle asthenia and ocular muscle atony: Rarely, statin drugs may cause or worsen severe muscle asthenia or ocular muscle atony. This drug should be used with caution in patients with these conditions. Administration should be discontinued if severe muscle atony or ocular muscle atony occurs or worsens.
6. Interaction
No pharmacokinetic drug interactions were observed in a drug interaction test conducted by administering 10 mg of amlodipine, 160 mg of valsartan, and 20 mg of rosuvastatin to healthy volunteers.
Studies on drug interactions with other drugs and amlodipine/valsartan/rosuvastatin combination were not conducted, but studies on individual drugs were conducted as follows.
1) Amlodipine
① Simvastatin: Multiple-dose co-administration of 10 mg of amlodipine and 80 mg of simvastatin increased the exposure of simvastatin by approximately 77% compared to administration of simvastatin alone. The maximum daily dose of simvastatin in patients receiving amlodipine is 20 mg.
② CYP3A4 inhibitor: When the elderly administered a combination of 5 mg of amlodipine and 180 mg of diltiazem per day, the systemic exposure of amlodipine increased by 57%. Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) may increase the blood concentration of amlodipine more than diltiazem, so amlodipine should be administered with caution when co-administered with CYP3A4 inhibitors.
③ CYP3A4 inducer: Co-administration with CYP3A4 inducer (e.g. rifampicin, St. John's wort) may change the plasma concentration of amlodipine. Therefore, blood pressure should be monitored and dose adjustments should be considered, especially during and after co-administration with strong CYP3A4 inducers.
④ Others: When amlodipine is administered alone, thiazide diuretics, alpha-blockers, beta-blockers, angiotensin converting enzyme inhibitors, long-acting nitrate preparations, nitroglycerin sublingual tablets, digoxin, warfarin, atorovastatin, sildenafil, aluminum/magnesium (antacid), cimetidine, non-steroidal drugs. It was safe when used in combination with anti-inflammatory drugs, antibiotics, oral hypoglycemic agents, ethanol (alcohol), and cyclosporine.
⑤ Grapefruit juice: When administered in combination with grapefruit juice, exposure to amlodipine may increase due to CYP3A4 inhibition. However, single oral administration of 240 mL of grapefruit juice and 10 mg of amlodipine to 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine.
⑥ Tacrolimus: When administered in combination with this drug, there is a risk of increasing the blood concentration of tacrolimus. Therefore, when administering this drug to patients being treated with tacrolimus, the blood concentration of tacrolimus should be monitored and the dosage of tacrolimus should be appropriately adjusted to avoid tacrolimus toxicity.
⑦ For additional drug interaction information, refer to the amlodipine single drug approval information.
2) Valsartan
① Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by co-administration of angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy with these drugs. In patients receiving valsartan concomitantly with other drugs that act on the RAAS, blood pressure, renal function, and electrolytes should be closely monitored. Valsartan and aliskiren-containing preparations should not be administered together to patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73m2).
② Potassium: Caution should be exercised when using potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other drugs that may increase potassium levels (e.g. heparin), and potassium levels should be monitored frequently.
③ Non-steroidal anti-inflammatory drugs (NSAIDs): The antihypertensive effect may be reduced when angiotensin II receptor antagonists are administered simultaneously with NSAIDs (e.g., aspirin as anti-inflammatory therapy, COX-2 inhibitors). In particular, the risk of kidney function deterioration may increase in elderly patients, patients with insufficient body fluids (including patients taking diuretics), or patients with reduced kidney function. Therefore, monitoring of renal function is recommended when starting valsartan or changing the administration method in patients taking NSAIDs.
④ Lithium: A reversible increase in serum lithium concentration and toxicity has been reported with co-administration of lithium preparations and ACE inhibitors or angiotensin II receptor antagonists. Therefore, monitoring of serum lithium concentrations is recommended during coadministration. If additional thiazide diuretics are used, the risk of lithium toxicity may increase.
⑤ Transporters: In vitro studies using human liver tissue showed that valsartan is a substrate for the liver uptake transporter OATP1B1 and the liver efflux transporter MRP2. Coadministration with uptake transporter inhibitors (rifampicin, cyclosporine) or efflux transporter inhibitors (ritonavir) may increase systemic exposure of valsartan.
⑥ When valsartan was administered alone, no clinically significant drug interactions were observed with the following drugs: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, and glibenclamide.
3) Rosuvastatin
① Effects of other drugs on rosuvastatin
In vitro and in vivo studies have shown that rosuvastatin does not interact clinically with cytochrome P450 (acting as a substrate, inhibitor or inducer).
Rosuvastatin is a substrate for some transporter proteins, such as the liver uptake drug transporter OATP1B1 and the efflux transporter BCRP. When inhibitors of these transporter proteins are used together with rosuvastatin, the blood concentration of rosuvastatin increases, which may increase the risk of myopathy.
Effects of other drugs
- Antacids: When rosuvastatin was co-administered with antacids containing aluminum hydroxide and magnesium hydroxide, the plasma concentration of rosuvastatin decreased by about 50%. However, this effect was alleviated when antacids were administered 2 hours after rosuvastatin. The clinical relevance of this interaction has not been studied.
- Fusidic acid: Interaction studies between rosuvastatin and fusidic acid have not been conducted. As with other statin drugs, muscle-related adverse reactions, including rhabdomyolysis, have been reported when rosuvastatin and fusidic acid were used together in post-marketing experience. Therefore, combined use of rosuvastatin and fusidic acid is not recommended. If possible, it is recommended to temporarily discontinue rosuvastatin administration, and if administration is unavoidable, close monitoring should be performed.
② Effect of rosuvastatin on other drugs
- Warfarin: When used in combination with rosuvastatin, warfarin has no significant effect on pharmacokinetics. However, like other HMG-CoA reductase inhibitors, coadministration of rosuvastatin and warfarin may increase the INR compared to administration of warfarin alone. INR monitoring is recommended when starting, stopping, or adjusting the dose of rosuvastatin in patients receiving vitamin K antagonists (e.g., warfarin).
- Cyclosporine: Co-administration of rosuvastatin and cyclosporine does not affect the blood concentration of cyclosporine.
- Fenofibrate/fibric acid derivatives: Pharmacokinetic interactions between fenofibrate and rosuvastatin were not observed, but pharmacokinetic interactions may occur. Gemfibrozil, fenofibrate, other fibrate-based drugs, and nicotinic acid in lipid-lowering doses (more than 1 g per day) can cause myopathy when administered alone, and therefore increase the risk of myopathy when administered in combination with HMGCoA reductase inhibitors. When co-administering fibrate-type drugs, administration of 40 mg of rosuvastatin is contraindicated, and 5 mg should be administered as the initial dose.
- Oral contraceptives: When administered in combination with oral contraceptives, the AUC of ethinyl oestradiol and norgestrel increased by 26% and 34%, respectively. This increase in plasma concentration should be taken into consideration when selecting the dosage of oral contraceptives. Since there is no pharmacokinetic data for patients taking rosuvastatin and HRT together, a similar effect should not be ruled out. However, in clinical trials, the combination was administered frequently in women and the tolerability was excellent.
- Effects on other drugs: There was no clinically significant interaction with digoxin or ezetimibe.
7. Administration to pregnant and lactating women
The safety of this drug in pregnant and lactating women has not been established, so it should not be used during pregnancy or lactation.
1) Pregnant women
① Amlodipine/valsartan combination drug
Because of the mechanism of action of angiotensin II antagonists, a risk to the fetus cannot be excluded. Damage to the developing fetus and death have been reported in pregnant women taking angiotensin-converting enzyme inhibitors (a special group of drugs that act on the renin-angiotensin-aldosterone system (RAAS)) during the second and third trimesters. And the use of ACE inhibitors in the first trimester is associated with a potential risk of fetal malformations. Spontaneous abortion, oligohydramnios, and renal dysfunction in newborns have been reported in pregnant women who accidentally took valsartan. Like other drugs that act directly on the RAAS, the amlodipine/valsartan combination should not be used during pregnancy or if you plan to become pregnant. When prescribing drugs that act on RAAS to women who may become pregnant, doctors should explain the potential risks of these drugs during pregnancy. If pregnancy is confirmed during amlodipine/valsartan combination therapy, this medication should be discontinued as soon as possible.
② Rosuvastatin
The safety of rosuvastatin in pregnancy has not been established and should not be used during pregnancy.
Women of childbearing potential should use appropriate contraception. Because cholesterol and cholesterol biosynthesis products are essential for fetal development, the potential risks of inhibiting HMG-CoA reductase outweigh the benefits of treatment during pregnancy. There is evidence of limited reproductive toxicity in animal studies. If you become pregnant while using rosuvastatin, you should stop taking it immediately.
2) Nursing mothers
In animal experiments, it was confirmed that valsartan and rosuvastatin were transferred into rat breast milk, and amlodipine was reported to be transferred into human breast milk. Therefore, this drug should not be administered during breastfeeding, and nursing mothers who are inevitably taking this medication should discontinue breastfeeding.
8. Administration to children
Safety and effectiveness in pediatric patients under 18 years of age have not been established, so administration of this drug is not recommended.
9. Administration to elderly people
No dose adjustment is necessary when administering this drug to the elderly, but it should be administered with caution as it cannot be ruled out that a more sensitive reaction may occur in some elderly patients. For elderly people over 75 years of age, the clearance rate of amlodipine is reduced, so start treatment at a low dose and gradually increase the dose.
In the case of elderly people, it is generally considered undesirable to lower blood pressure excessively due to the risk of cerebral infarction, etc., so administration should be done carefully while observing the patient's condition, such as starting from a low dose. In a pharmacokinetic test on elderly people, the blood concentration of valsartan was found to be higher than that of non-elderly people.
10. Effect on clinical test values
1) Among patients with hypertension who received valsartan/amlodipine, there were very few patients whose test values clearly changed from baseline. The amlodipine/valsartan combination group (5.5%) and the valsartan alone group (5.5%) showed higher blood urea nitrogen (BUN) than the placebo group (4.5%).
2) An increase in liver function test values has occasionally been reported when administering valsartan, but special monitoring of clinical test values is not necessary for patients with essential hypertension taking this drug.
11. Treatment in case of overdose
I have no experience of overdosing on this drug. Experience with overdose of each single agent is as follows.
1) Amlodipine
Current data indicate that severe overdose may result in reflex tachycardia along with excessive peripheral vasodilation. In addition, it has been reported that symptoms of systemic hypotension are severe and persist for a long time, leading to a state of shock or resulting in fatal shock. When activated charcoal was administered to healthy volunteers immediately or up to 2 hours after administering 10 mg of amlodipine, the absorption of amlodipine was significantly reduced. In some cases, gastric lavage may be useful. Clinically serious hypotension caused by overdose of this drug requires active supportive treatment for the cardiovascular system, such as frequent monitoring of heart and respiratory function, maintaining the position of the limbs higher than the body, and ensuring sufficient circulating fluids such as blood and urine excretion. Unless there are special cases where the use of vasoconstrictors is contraindicated, vasoconstrictors may be useful in restoring vascular tone and blood pressure. Intravenous administration of calcium gluconate may be useful in reversing the effects of calcium channel inhibitors. Because amlodipine has a very high protein binding rate, hemodialysis is not helpful. Non-cardiogenic pulmonary edema has been rarely reported following amlodipine overdose. This may occur delayedly (24-48 hours after taking the dose) and may require ventilatory support. Early resuscitative measures to maintain perfusion and cardiac output (including fluid overload) may be precipitating factors.
2) Valsartan
Although there is no experience with valsartan overdose, significant hypotension, decreased consciousness, circulatory collapse and shock, tachycardia, and bradycardia due to parasympathetic nerve stimulation are expected. Immediately after taking the drug, induce vomiting or administer medicinal charcoal. Otherwise, inject physiological saline into a vein. If low blood pressure occurs, the patient should be placed in a supine position and blood volume should be corrected. Hemodialysis does not help.
3) Rosuvastatin
There is no special treatment in case of overdose. In case of overdose, symptomatic and supportive treatment should be administered. Liver function and CK levels should be monitored. Hemodialysis does not appear to help.
12. Information for professionals
1) Pharmacological action
(1) Amlodipine: It is a calcium channel blocker (CCB)-based treatment for high blood pressure. It relaxes vascular smooth muscles by blocking the calcium ion channels on the surface of myocardial and vascular smooth muscles, and increases the glomerular filtration rate by relaxing the afferent arterioles of the kidneys, thereby causing diuresis and lowering blood pressure.
(2) Valsartan: A member of the angiotensin II receptor blocker (ARB) class, it selectively and competitively antagonizes the angiotensin II receptor, a powerful vasoconstrictor, causing an increase in blood renin concentration, thereby relaxing the veins and lowering blood pressure.
(3) Rosuvastatin: 3-hydroxy-3 methylglutaryl-coenzyme A (HMG-A) reductase inhibitor. This is a drug that inhibits HMG-CoA reductase, which plays a role in catalyzing the conversion of HMG-A to mevalonate in the initial rate control stage of cholesterol biosynthesis.
2) Pharmacokinetic information
(1) One biopharmaceutical test was conducted to compare the bioavailability of this drug (amlodipine/valsartan/rosuvastatin) and the combined administration of approved drugs (amlodipine/valsartan combination and rosuvastatin single drug). A total of 48 healthy adults were administered a single dose of 10/160 mg of amlodipine/valsartan and 20 mg of rosuvastatin on an empty stomach as a three-drug combination or an approved drug (2×4 cross-over study). When the pharmacokinetic parameters were compared by measuring the blood concentrations of amlodipine, valsartan, and rosuvastatin, the 90% confidence intervals of the log-transformed mean difference of the comparative evaluation item values (AUClast, Cmax) were all within the range of bioequivalence.
(2) One comparative pharmacokinetic study was conducted to evaluate the pharmacokinetic drug interaction of amlodipine/valsartan and rosuvastatin. A total of 57 healthy adults participated and took 20 mg of rosuvastatin and 10/160 mg of amlodipine/valsartan combination alone or in combination for 17 days (2×2 crossover test). As a result of the test, no pharmacokinetic interaction was observed.
(3) Although not a test conducted with this drug, rosuvastatin increased the median AUC and Cmax approximately two-fold in Asians (Japan, China, Philippines, Vietnam, Korea) compared to Caucasians. Demographic pharmacokinetic analysis showed no clinically meaningful pharmacokinetic differences between Caucasians and blacks.
3) Clinical trial information
One randomized, double-blind, parallel group trial was conducted to comparatively evaluate the effectiveness and safety of amlodipine/valsartan/rosuvastatin combination or amlodipine/valsartan combination or valsartan/rosuvastatin combination for 8 weeks in 175 patients (Safety set) with both hypertension and dyslipidemia.
Before randomization, subjects were administered 160 mg of valsartan once a day during a therapeutic lifestyle correction period of at least 4 weeks. After the therapeutic lifestyle correction period, subjects who met the criteria according to the NCEP ATP III risk with an average systolic blood pressure of more than 140 mmHg but less than 180 mmHg, TG less than 400 mg/dL, and LDL-C were eligible for this drug (amlodipine/valsartan). Patients were randomly assigned to receive 10/160 mg and rosuvastatin 20 mg), amlodipine/valsartan 10/160 mg, or valsartan and rosuvastatin 160/20 mg.
As co-primary efficacy endpoints, the change in msSBP of this drug compared to the valsartan and rosuvastatin group and the LDL-C change rate (%) of this drug compared to the amlodipine/valsartan group were evaluated.
When an analysis of covariance (ANCOVA) was performed on the primary efficacy endpoints, the amount of change in msSBP and the rate of change in LDL-C levels compared to the baseline, with the mean value of the baseline adjusted as a covariate, the change in msSBP and the rate of change in LDL-C in the test group were superior to those in the respective control groups (p<0.0001).
4) Toxicity test information
(1) Repeated dose toxicity
A repeated dose toxicity test was conducted in rats in which the test substances (amlodipine/valsartan/rosuvastatin) were orally administered for 13 weeks, and no new unknown toxicological changes were observed in each single ingredient.
(2) Reproductive and developmental toxicity
Although additional reproductive and developmental toxicity tests were not conducted for the development of combination drugs, the known reproductive and developmental toxicity for each single drug is as follows.
① Amlodipine
Other than delayed and prolonged parturition in rats administered amlodipine at a dose equivalent to 50 times the maximum recommended dose for humans, no reproductive toxicity has been proven in animals.
② Valsartan
A decreased survival rate and a slight delay in physical development were observed in the offspring of rats administered 600 mg/kg/day during the last 3 months of pregnancy and lactation.
In a rat fertility test, it was observed that oral administration up to 200 mg/kg/day, which is approximately 6 times the maximum recommended dose (MRHD) for humans based on body surface area (mg/m2), did not affect the fertility of male or female rats.
In embryo-fetal development tests on mice, rats, and rabbits, fetal toxicity associated with maternal toxicity was observed in rats administered 600 mg/kg/day and rabbits administered 10 mg/kg/day. These doses are 18 and 0.6 times the maximum recommended human dose, respectively, based on body surface area (mg/m2) (assuming an oral dose of 320 mg/day for a 60 kg patient). There was no evidence of maternal or fetal toxicity in mice dosed up to 600 mg/kg/day, which is 9 times the maximum recommended human dose based on body surface area (mg/m2).
③ Rosuvastatin
In prenatal and postnatal developmental tests in rats, reproductive toxicity was observed, including reduced litter size, reduced litter weight, and reduced survival of the next generation. This effect was observed when a dose equivalent to several times the therapeutic dose was administered systemically to the mother.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
36 months from date of manufacture
- Active ingredient: Amlodipine besylate (USP) ---------- 13.87mg (10mg as amlodipine)
Valsartan (USP) -------------------- 160mg
Rosuvastatin Calcium (EP) ------------ 10.40mg (10mg as rosuvastatin)
- Additives: Anhydrous calcium hydrogen phosphate, microcrystalline cellulose, magnesium stearate, Opadry pink (03B640002), low-substituted hydroxypropyl cellulose, colloidal silicon oxide, crospovidone
2. Effectiveness
This drug is only used in patients who need to take amlodipine/valsartan combination and rosuvastatin simultaneously.
▷ Amlodipine/valsartan combination drug
Essential hypertension whose blood pressure is not adequately controlled with amlodipine or valsartan monotherapy
▷ Rosuvastatin
1. Primary hypercholesterolemia (type IIa including heterozygous familial hypercholesterolemia), combined dyslipidemia (type IIb)
: Dietary supplement in cases that cannot be controlled through diet and exercise
2. Adjuvant to diet or other lipid-lowering therapy (e.g. LDL apheresis) for homozygous familial hypercholesterolemia
3. Delays the progression of atherosclerosis by lowering total cholesterol and LDL-cholesterol to target levels in patients with hypercholesterolemia.
4. Dietary supplement for patients with primary dysbetalipoproteinemia (type III)
5. Reduces risk for cardiovascular disease
: Patients with no clinical evidence of coronary heart disease, but who are men over 50 years of age and women over 60 years of age, have a high sensitive C-reactive protein (hsCRP) of 2 mg/L or more, and have at least one additional cardiovascular disease risk factor (e.g. high blood pressure, low HDL-cholesterol level, smoking, or family history of premature coronary heart disease, etc.)
- Reduced risk of stroke
- Reduced risk of myocardial infarction
- Reduced risk of arterial revascularization
3. Dosage and dosage
Take this medicine 1 tablet once a day with water. If possible, it is recommended to take it at the same time every day (e.g. before breakfast).
This drug is administered only to adults, and the dosage should be individualized for each patient based on the effectiveness and tolerability of the amlodipine/valsartan combination and rosuvastatin.
For patients who are taking a combination of amlodipine/valsartan and rosuvastatin as a single drug, they can switch to this drug (a combination drug with the same content of each active ingredient) for convenience of administration.
▷ Amlodipine/valsartan combination drug
It is recommended to adjust the dose of the individual ingredients (amlodipine or valsartan) before administering the amlodipine/valsartan combination medication. However, if blood pressure is not controlled with monotherapy with each ingredient as follows, switching directly to the amlodipine/valsartan combination medication can be considered.
ㆍ5/80 mg: Administered to patients whose blood pressure is not adequately controlled with monotherapy with 5 mg of amlodipine or 80 mg of valsartan.
ㆍ5/160 milligrams: Administered to patients whose blood pressure is not adequately controlled with monotherapy with 5 milligrams of amlodipine or 160 milligrams of valsartan.
ㆍ10/160 milligram: Administer to patients whose blood pressure is not properly controlled with 10 milligrams of amlodipine or 160 milligrams of valsartan alone or with 5/160 milligrams.
Patients with renal impairment: No dosage adjustment is necessary for patients with mild or moderate renal impairment (creatinine clearance of 10 mL/min or more), but patients with severe renal impairment (creatinine clearance of less than 10 mL/min) and dialysis patients do not receive amlodipine/valsartan combination medication. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended.
Patients with hepatic impairment: For patients with mild and moderate hepatic impairment, the daily dose of valsartan should not exceed 80 mg. Amlodipine/valsartan combination medication should not be administered to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or bile secretion arrest.
Elderly people over 65 years of age: Caution should be exercised when increasing the dose.
▷ Rosuvastatin
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbeta-lipoproteinemia (type III), and homozygous familial hypercholesterolemia.
Patients before and while receiving rosuvastatin should follow a standard cholesterol-lowering diet and continue this during the treatment period. Rosuvastatin can be administered at any time of the day, regardless of meals. The initial dose is 5 milligrams once a day, and if further LDL-cholesterol level reduction is required, the maintenance dose can be adjusted. The maintenance dose is 10 milligrams once a day, and most patients are adjusted to this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more depending on the LDL-cholesterol level, treatment goals, and patient response, and the dose can be increased up to 20 milligrams per day.
2. Elderly: No dosage adjustment is necessary.
3. Patients with renal failure: For patients with mild to moderate renal failure, there is no need to adjust the dose. Do not administer to patients with severe renal failure. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal failure.
4. Patients with liver failure: There was no increase in systemic exposure to rosuvastatin in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score exceeding 9. Rosuvastatin is not administered to patients with active liver disease.
5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of doses of 40 milligrams is contraindicated.
6. Patients prone to myopathy: The recommended initial dose for patients prone to myopathy is 5 milligrams. In some of these patients, administration of rosuvastatin at a dose of 40 mg is contraindicated.
4. Precautions for use
1. Warning
When drugs that act directly on the renin-angiotensin system are administered to pregnant women in the second or third trimester of pregnancy, they can cause damage and even death to the fetus and newborn. Therefore, if pregnancy is confirmed, administration of this drug should be discontinued immediately. (Refer to ‘2. Do not administer to the following patients’ and ‘7. Administration to pregnant and lactating women’)
2. Do not administer to the following patients
1) Patients with hypersensitivity to the components or dihydropyridine derivatives of this drug
2) Pregnant women, women who may be pregnant, and lactating women
3) Patients with severe liver dysfunction, biliary cirrhosis, biliary obstruction, and bile secretion arrest
4) Patients with active liver disease, including persistent serum transaminase elevations of unknown cause or serum transaminase elevations exceeding 3 times the upper limit of normal.
5) Patients with severe renal impairment (creatinine clearance less than 30mL/min)
6) Combination use with aliskiren-containing preparations in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2)
7) Patients with hereditary angioedema or a history of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
8) Patients with primary hyperaldosteronism (This drug is not administered to patients with primary hyperaldosteronism because the renin-angiotensin-aldosterone system is not activated.)
9) Patients with severe aortic stenosis
10) Shock patients
11) Patients with myopathy
12) Patients taking cyclosporine concurrently
13) Rosuvastatin administration at a dose of 40 mg is contraindicated in patients prone to myopathy/rhabdomyolysis. These factors are as follows.
- Moderate renal impairment (creatinine clearance < 60ml/min)
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA converting enzyme or fibrate drugs
- alcoholism
- Situations in which plasma concentrations may increase
- Asian patient
- Concomitant administration of fibrate-based drugs
3. Administer with caution to the following patients:
1) Patients with sodium and/or fluid deficiency
In a placebo-controlled clinical trial, excessive hypotension was observed in 0.4% of patients with uncomplicated hypertension who received the amlodipine/valsartan combination. In patients with an activated renin-angiotensin system who are taking angiotensin receptor antagonists (ARB antagonists) (e.g., volume and/or sodium depleted patients taking high doses of diuretics), symptomatic hypotension may occur. It is recommended that these conditions be corrected prior to administration of this drug or that close medical observation be observed upon initiation of treatment.
If low blood pressure occurs when taking this medicine, have the patient lie down and, if necessary, inject saline solution intravenously. Treatment can be continued after blood pressure stabilizes.
2) Patients with hyperkalemia
Caution should be exercised when coadministering this drug with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other drugs that may increase potassium levels (e.g. heparin), and potassium levels should be monitored frequently.
3) Patients with renal artery stenosis
This drug may increase blood urea and serum creatinine in patients with bilateral or unilateral renal artery stenosis caused by valsartan or in patients with short stature and stenosis, so monitoring is recommended for safety.
4) Kidney transplant patient
There are no data to demonstrate the safe use of this drug in patients who have recently undergone a kidney transplant.
5) Angioedema
Angioedema (including swelling of the larynx and glottis) causing airway obstruction and/or swelling of the face, lips, and tongue has been reported in patients receiving valsartan. Some of these patients had experienced angioedema caused by other medications, such as ACE inhibitors. If angioedema occurs during administration of this drug, administration should be discontinued immediately and should not be re-administered.
6) Patients after heart failure or myocardial infarction
In general, caution is advised when using calcium channel antagonists such as amlodipine in patients with severe congestive heart failure (NYHA class III or IV). In a placebo-controlled trial (PRIASE-2) in patients with NYHA stage III or IV heart failure of nonischemic origin, amlodipine was reported to be associated with an increase in pulmonary edema despite clearly reducing exacerbations of heart failure compared to placebo.
In patients whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system (e.g., severe heart failure), administration of angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
7) Patients with acute myocardial infarction
An increase in the frequency, duration, or severity of angina pectoris or acute myocardial infarction has been rarely reported in patients (particularly those with severe obstructive coronary artery disease) who started taking or increased the dose of a calcium channel blocker (e.g., amlodipine).
8) Patients with aortic and mitral valve stenosis and obstructive hypertrophic cardiomyopathy
As with all other vasodilators, special caution is required when administering amlodipine to patients with aortic or mitral atresia or obstructive hypertrophic cardiomyopathy.
9) Patients with severe muscle atony or ocular muscle atony
Cases of recurrence have been reported when the same or different types of statin drugs were administered.
10) Dual blockade of renin-angiotensin-aldosterone system (RAAS)
Concomitant use with other drugs that affect the renin-angiotensin-aldosterone system (RAAS), such as angiotensin receptor blockers (ARBs), ACE inhibitors, or aliskiren, including valsartan, is not recommended.
11) Patients with mild to moderate hepatic impairment (In patients with mild to moderate hepatic impairment, it is recommended that the daily dose of valsartan among the ingredients of this drug do not exceed 80 mg.)
12) Like other HMG-CoA reductase inhibitors, rosuvastatin should be administered with caution to patients who consume excessive alcohol or have a history of liver disease. It is recommended that liver enzyme tests be performed repeatedly as clinically necessary before and after starting rosuvastatin treatment. Patients with hypercholesterolemia secondary to hypothyroidism or nephrotic syndrome must treat the causative disease before administering rosuvastatin.
13) As with other HMG-CoA reductase inhibitors, effects on skeletal muscle, such as myalgia and myopathy, and rarely rhabdomyolysis, have been reported in patients receiving rosuvastatin. Immune-mediated necrotizing myopathy has been reported in patients taking or discontinuing statins, including rosuvastatin. Immune-mediated myopathy is clinically characterized by weakened proximal muscles and increased CK (creatine kinase) in the blood, and the symptoms persist even after discontinuation of treatment.
· As with other HMG-CoA reductase inhibitors, the risks and benefits of treatment should be considered in the following patients with factors predisposing to myopathy/rhabdomyolysis, and clinical monitoring is recommended. Treatment should not be started if the CK (creatine kinase) value is significantly increased from the baseline level (more than 5 times the upper limit of normal) before treatment.
- Patients with renal impairment
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA reductase inhibitors or fibrates.
- alcohol abuse
- Seniors over 70 years old
- Situations in which plasma concentrations may increase
- Concomitant administration of fibrate-based drugs
· During treatment, unexplained muscle pain, muscle weakness or cramps should be reported immediately, especially if associated with malaise or fever. In these patients, the CK level should be measured, and if the CK level is significantly elevated (more than 5 times the upper limit of normal) or if the muscle symptoms are severe and cause daily discomfort even if the CK level increases below 5 times the upper limit of normal, administration of this drug should be discontinued. Once symptoms resolve and CK levels return to normal, consideration should be given to restarting rosuvastatin or another HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels is not necessary in asymptomatic patients.
· Because it may make interpretation of the measurement results difficult, do not measure CK after intense exercise or when there are other causes that may increase the CK value. If the CK value increases significantly from baseline (more than 5 times the upper limit of normal), a confirmatory test should be performed within 5 to 7 days. Even when repeating the test, this drug should not be administered if the baseline CK value increases more than 5 times the upper limit of normal.
14) This drug should be discontinued in acute severe conditions that suggest worsening of myopathy or renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, wounds, severe metabolic/endocrine/electrolyte diseases, uncontrolled epileptic seizures).
15) In clinical trials, there was no evidence of increased effects on skeletal muscle in the small number of patients who received rosuvastatin in combination with other drugs. However, in the case of other HMG-CoA reductase inhibitors, the frequency of myositis and myopathy increased in patients receiving concurrent treatment with fibric acid derivatives (including gemfibrozil), cyclosporine, nicotinic acid, azole antifungals, protease inhibitors, and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when combined with HMG-CoA reductase inhibitors. Therefore, the combined use of this drug and gemfibrozil is not recommended. When administering this drug in combination with fibrates or niacin, the benefits and risks should be carefully evaluated. A dose of 40 milligrams of rosuvastatin is contraindicated when coadministered with fibrate-based drugs.
16) In patients taking high doses of rosuvastatin, especially 40 mg, proteinuria, mostly of tubular origin, detected by dipstick test was observed. This is usually transient and is not a predictor of acute or progressive renal failure. Renal function tests should be considered during the follow-up period for patients receiving 40 mg.
17) According to a pharmacokinetic study of rosuvastatin, an increase in systemic exposure (median AUC and Cmax approximately 2-fold increase) was observed in Asians compared to Caucasians, so this should be taken into consideration when determining dosage for Asians.
4. Adverse reactions
1) Amlodipine/valsartan/rosuvastatin combination drug
The safety of this drug was evaluated in a clinical trial in which 175 patients with both hypertension and dyslipidemia were administered a combination of amlodipine/valsartan and rosuvastatin (58 patients), a combination of amlodipine/valsartan (58 patients), or a combination of valsartan and rosuvastatin (59 patients) for 8 weeks.
The adverse reactions reported in the amlodipine/valsartan combination and rosuvastatin combination group (58 patients), regardless of causal relationship with the test drug, are as follows.
[See Table 1]
2) Information collected from amlodipine/valsartan combination medication
(1) The safety of the amlodipine/valsartan combination was evaluated from 5 controlled clinical trials in which 5,175 patients participated, 2,613 of whom received amlodipine and valsartan in combination.
Adverse reactions were classified according to frequency of occurrence into very common (≥ 1/10), common (≥ 1/100, <1/10), uncommon (≥ 1/1,000, <1/100), rare (≥ 1/10,000, <1/1,000), and very rare (<1/10,000), including independent reports. In the same frequency group, adverse reactions were organized in decreasing order of seriousness.
[See Table 2]
(2) Additional information on combined use
In a double-blind, drug- or placebo-controlled clinical trial, the incidence of peripheral edema was statistically lower in the combination treatment group (5.8%) compared to the amlodipine treatment group alone (9%).
(3) Domestic post-marketing survey results
① As a result of a usage results survey conducted on 859 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 5.12% (44 people, 56 cases) regardless of causal relationship.
The incidence of adverse drug reactions for which a causal relationship with the amlodipine/valsartan combination cannot be ruled out was 1.75% (15 people, 19 cases), headache 0.47% (4 people, 4 cases), dizziness 0.35% (3 people, 3 cases), itching 0.35% (3 people, 3 cases), peripheral edema 0.23% (2 people, 2 cases), Low blood pressure was observed in 0.23% (2 people, 2 cases), and edema, chest pain, pain, cough, and enuresis were observed in 1 case each.
No serious adverse events were reported regardless of causal relationship with the amlodipine/valsartan combination. As unexpected adverse events, a total of 9 cases were reported: chest discomfort 0.23% (2 people, 2 cases), pain, abdominal discomfort, reflux esophagitis, neck pain, hypercholesterolemia, hypoglycemia, and enuresis. A total of 2 unexpected adverse drug reactions occurred, 1 case of pain and 1 case of enuresis.
② As a result of integrated evaluation of the domestic re-examination adverse event and spontaneous side effect report data for the amlodipine/valsartan combination drug with the adverse event report data reported for all drugs approved for domestic marketing at the end of the re-examination, the newly identified adverse events that were statistically significantly more reported in the amlodipine/valsartan combination drug compared to the adverse cases reported in all other drugs are as follows. However, this result does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
· Systemic abnormalities: chest pain, weight gain
· Musculoskeletal system: joint pain, skeletal pain, rhabdomyolysis
· Oral: Gum hyperplasia
· Gastrointestinal system: gastritis
· Mental disorder: nervousness
· Nervous system: decreased sensation
· Skin and subcutaneous tissue abnormalities: Stevens-Johnson syndrome
3) Information collected from valsartan/rosuvastatin combination medication
※ Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 698 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 14.90% (104/698 people, 137 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
[See Table 3]
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
[See Table 4]
4) Information collected from amlodipine/rosuvastatin combination medication
(1) Domestic post-marketing surveillance results following re-examination
As a result of a post-marketing survey conducted on 654 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 26.30% (172/654 people, 237 cases) regardless of causal relationship. Among these, no serious adverse drug reactions for which a causal relationship cannot be ruled out were reported, and unexpected adverse drug reactions are listed in the table below according to their frequency of occurrence.
[See Table 5]
5) Additional information on individual active ingredients
Although not observed in clinical trials and post-marketing experience with this drug, adverse reactions previously reported for each component may occur.
(1) Amlodipine
Regardless of the causal relationship with the drug, adverse reactions reported in amlodipine clinical trials are listed in <Table 3>.
[See Table 6]
Gynecomastia has been rarely reported during post-marketing use, but the causal relationship with amlodipine is not clear. Additionally, jaundice and elevated liver enzymes (most often consistent with biliary dysfunction or hepatitis) have been reported to be associated with amlodipine administration, and some cases were severe enough to require hospitalization. Leukopenia, thrombocytopenia, confusion, exfoliative dermatitis, Stevenson-Johnson syndrome, photosensitivity reaction, and toxic epidermal necrolysis have been reported (frequency unknown).
For additional safety information, refer to the amlodipine single-substance labeling.
(2) Valsartan
[See Table 7]
Regardless of the causal relationship with the drug, the following symptoms were reported during clinical trials: insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, and viral infection.
Intestinal angioedema has been reported during post-marketing use (very rarely).
For additional safety information, refer to the valsartan single-substance labeling.
(3) Rosuvastatin
① Reported adverse reactions were generally mild and transient. Less than 4% of patients in the rosuvastatin treatment group discontinued the study due to adverse reactions.
The frequency of adverse reactions was classified as follows: common (>1/100, <1/10); Uncommon (>1/1,000, <1/100); Rare (>1/10,000, <1/1,000); Very rare (<1/10,000). Not known (cannot be estimated from available data)
As with other HMG-CoA reductase inhibitors, adverse reactions tended to increase as the dose increased.
② Effect on kidneys: Proteinuria, mostly of tubular origin, detected by dipstick test, was observed. The phenomenon of conversion of urine protein from negative or very small amounts to ++ or higher occurred in less than 1% of cases at 10 or 20 milligrams and in about 3% of cases at 40 milligrams. A slight increase in urine protein from negative or very small amounts to + was also observed at the 20 mg dose. Proteinuria decreased or disappeared spontaneously during treatment in most cases and is not a predictor of acute or progressive renal failure. Hematuria was observed in patients and clinical trial data administered rosuvastatin, but the frequency of occurrence was low.
③ Effects on the musculoskeletal system: Effects on the musculoskeletal system with or without acute renal failure (e.g., myalgia, myopathy (including myositis), rarely rhabdomyolysis, etc.) have been reported in patients treated with all doses of rosuvastatin (especially 20 mg or more). In the patient group receiving rosuvastatin, creatinine kinase (CK) levels increased in a dose-dependent manner. In most cases, it was mild, asymptomatic, and transient. If creatinine kinase (CK) levels increase significantly (more than 5 times the upper normal limit), treatment should be temporarily discontinued.
④ Effect on the liver: As with other HMG-CoA reductase inhibitors, transaminase levels increased in a dose-dependent manner in a small number of patients receiving rosuvastatin. In most cases, it was mild, asymptomatic, and transient.
⑤ Overseas post-marketing experience
In addition to the above adverse reactions, the following adverse reactions were reported during post-marketing surveillance.
- Nervous system: Very rare polyneuropathy, amnesia, peripheral neuropathy (frequency unknown)
- Respiratory system and chest: cough, difficulty breathing (frequency unknown)
- Gastrointestinal system: Diarrhea (frequency unknown)
- Hematological disorders: Thrombocytopenia (frequency unknown)
- Hepatobiliary system: very rare, jaundice, hepatitis, rarely increased transaminases
- Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (frequency unknown), drug reaction syndrome with increased eosinophils and systemic symptoms (DRESS) (frequency unknown)
- Musculoskeletal system: Rarely lupus-like syndrome, muscle rupture, very rarely arthralgia, immune-mediated necrotizing myopathy (frequency unknown)
- Kidney: Very rare hematuria
- Other: Edema (frequency unknown)
The following adverse reactions have been reported in relation to some statin drugs.
- Mental nervous system: depression, sleep disorders (including insomnia and nightmares) (frequency unknown)
- Respiratory system: Exceptional cases such as interstitial lung disease, especially during long-term administration
- Urogenital system: sexual dysfunction, gynecomastia (frequency unknown)
- Hepatobiliary system: Fatal and non-fatal liver failure
There have been rare reports of post-marketing cognitive impairment associated with statin use. (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) Such cognitive impairment has been reported with all statin drugs. These reports are generally not serious and reversible after discontinuation of drug use, but there is variation in the time of symptom onset (1 day to several years) and symptom improvement (median 3 weeks). The induction or worsening of severe muscle atony or ocular muscle atony has been reported with the administration of statin drugs.
⑥ Domestic post-marketing survey results
As a result of a usage outcome survey conducted on 3,081 people over 6 years for re-examination in Korea, regardless of causal relationship, the occurrence rate of adverse events was 10.06% (310 people, 415 cases), mainly headache 0.78% (24 people, 24 cases), dizziness 0.75% (23 people, 23 cases), and ALT increase 0.58% (18 people, 18 cases). 18 cases), chest pain, cough, and muscle pain were reported in 0.49% (15 people, 15 cases) each, and of these, 2.92% (90 people, 106 cases) of adverse drug reactions for which a causal relationship with rosuvastatin could not be ruled out.
The most common adverse drug reactions reported were ALT increase at 0.55% (17 people, 17 cases), muscle pain at 0.42% (13 people, 13 cases), headache at 0.39% (12 people, 12 cases), CK increase at 0.29% (9 people, 9 cases), dizziness at 0.26% (8 people, 8 cases), constipation, and AST increase. 0.16% (5 people, 5 cases), asthenia and joint pain each at 0.13% (4 people, 4 cases), fatigue and numbness at 0.10% each (3 people, 3 cases), paresthesia, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, itching, liver function test abnormalities at 0.06% each (2 people, 2 cases), syncope, systemic pain, Muscle cramps, gout, and erectile dysfunction each occurred in 0.03% (1 person, 1 case). Among these, muscle pain and joint pain in one patient were serious adverse drug reactions, and unexpected adverse drug reactions that did not appear before marketing included joint pain in 0.13% (4 patients, 4 cases), fatigue and numbness in 0.10% (3 patients, 3 cases), paresthesia, chest discomfort, loss of appetite, abdominal distension, and liver function test abnormalities in 0.06% (2 patients, 2 cases) respectively, syncope, and General pain, muscle cramps, gout, and erectile dysfunction occurred in 0.03% (1 person, 1 case) each, and one case of joint pain was reported as a serious and unexpected adverse drug reaction.
There were 98 adverse events voluntarily reported during the re-examination period, of which 2 cases of acute renal failure and 1 case each of oliguria, thrombocytopenia, and increased blood creatinine were reported as serious and unexpected adverse drug reactions.
5. General precautions
1) Be careful when driving and operating machines
Clinical trials have not been conducted on the effects on driving and using machinery. It should be taken into account that dizziness and fatigue may occur intermittently when driving or using machinery. As with other antihypertensive drugs, take special care when driving or operating machinery.
2) Amlodipine
(1) Administration to patients with heart failure: In the long-term, placebo-controlled trial (PRAISE-2) of amlodipine in patients with NYHA class III and IV heart failure without ischemic etiology, amlodipine was associated with an increase in reports of pulmonary edema despite no significant difference in the worsening rate of heart failure compared with placebo.
(2) Administration to patients with impaired liver function: Like all calcium antagonists, the half-life of amlodipine is prolonged in patients with impaired liver function, and the recommended dosage for these patients has not been established. Therefore, administer with caution to these patients.
(3) Because the plasma concentration half-life is long, a gradual blood pressure lowering effect appears even after discontinuation of administration, so when administering other antihypertensive drugs after discontinuation of administration, pay attention to the dosage and administration interval and administer carefully while observing the patient's condition.
(4) Since the effect appears slowly, it cannot be expected to be effective in unstable angina pectoris that requires emergency treatment.
3) Valsartan
(1) Administration of valsartan may cause a rapid temporary drop in blood pressure (accompanied by fainting and loss of consciousness, etc.) after the first administration, so in such cases, discontinue administration and take appropriate measures. In addition, especially in the following patients, administration should be started at a low dose and the dose increased slowly while carefully observing the patient's condition.
① Patients undergoing hemodialysis
② Patients taking diuretics (especially in patients with severe sodium deficiency or volume deficiency, caution may occur in rare cases of symptomatic hypotension).
③ Patients undergoing strict salt restriction
(2) In patients with severe sodium depletion or body fluid depletion due to taking high doses of diuretics, hypotension may rarely occur in the early stages of valsartan administration. Before valsartan administration, this depletion of sodium and body fluid must be corrected by methods such as reducing the diuretic dose. If low blood pressure occurs, have the patient lie down in an upright position and, if necessary, inject physiological saline solution by drip. Continue drug administration after blood pressure stabilizes.
(3) Patients with renal artery stenosis: Short-term administration of valsartan to 12 patients with renovascular hypertension accompanied by secondary unilateral renal artery stenosis did not induce significant changes in renal hemodynamics, serum creatinine, and BUN. However, when other drugs that affect the renin-angiotensin-aldosterone system are administered to patients with bilateral or unilateral renal artery stenosis, blood urea and serum creatinine may increase, so monitoring is recommended for safety reasons. In patients with bilateral or unilateral renal artery stenosis, there is a risk of rapid deterioration of renal function due to decreased renal blood flow and decreased glomerular filtration pressure, so administration should be avoided except in cases where treatment is deemed unavoidable.
(4) It is desirable that the daily dose of valsartan for patients with mild to moderate hepatic impairment does not exceed 80 mg. Valsartan is mostly excreted in bile as an unchanged form and has a low clearance rate in patients with biliary obstruction, so it is not used in these patients. It has been reported that when valsartan is administered to patients with mild to moderate hepatic impairment, the plasma concentration increases approximately twice that of healthy adults.
(5) Patients receiving valsartan after heart failure or myocardial infarction mainly experience a decrease in blood pressure, but there is no need to discontinue treatment due to persistent symptoms of hypotension. Caution should be exercised when initiating treatment in patients with heart failure or after a myocardial infarction.
As a result of inhibition of the renin-angiotensin-aldosterone system, changes in renal function are expected in susceptible patients. Treatment with ACE inhibitors and angiotensin II receptor antagonists in patients with severe heart failure whose renal function is dependent on the activity of the renin-angiotensin-aldosterone system has been associated with oliguria and/or progressive azotemia and (rarely) acute renal failure and/or death. Similar results have been reported with valsartan. Evaluation of patients after heart failure or myocardial infarction should always include evaluation of renal function.
Triple therapy of ACE inhibitors, beta-blockers, and valsartan is not recommended in patients with heart failure. This is because simultaneous administration of beta-blockers and ACE inhibitors increases morbidity and mortality due to heart failure.
Increases in BUN, creatinine, and potassium levels have been observed in some heart failure patients. This phenomenon is mainly mild and temporary, and is likely to occur in patients with pre-existing renal damage. Dosage reduction and discontinuation of valsartan and/or diuretics should be considered.
(6) In patients with hyperkalemia, administration should be avoided except in cases where treatment is deemed unavoidable as there is a risk of worsening hyperkalemia. Additionally, patients who are prone to elevated serum potassium levels due to kidney dysfunction, diabetes, etc., may develop hyperkalemia, so pay attention to serum potassium levels.
(7) There is no experience of use in patients who recently underwent kidney transplantation.
(8) Intestinal angioedema has been reported in patients receiving angiotensin II receptor antagonists. These patients presented with abdominal pain, nausea, vomiting, and diarrhea. Symptoms resolved after discontinuation of angiotensin II receptor antagonist. If intestinal angioedema is diagnosed, treatment should be discontinued and appropriate monitoring should be conducted until symptoms completely resolve.
4) Rosuvastatin
(1) Interstitial lung disease: Unusual cases such as interstitial lung disease have been reported with some statin drugs, especially during long-term administration. Presenting symptoms may include difficulty breathing, cough without phlegm, and general deterioration in health (fatigue, weight loss, and fever). If a patient is suspected of developing interstitial lung disease, statin drug treatment should be discontinued.
(2) Post-marketing cases of fatal and non-fatal liver failure have been rarely reported in patients taking statin drugs, including rosuvastatin. If severe liver damage and/or hyperbilirubinemia or jaundice with clinical symptoms occurs while taking this drug, treatment should be discontinued immediately. Do not re-administer this drug if no other etiology is found.
(3) Increases in HbA1c and fasting blood sugar levels were reported when administering HMG-CoA reductase inhibitors, including rosuvastatin.
(4) Diabetes: Some evidence suggests that hyperglycemia, which requires appropriate diabetes treatment, may occur in some patients at high risk of developing diabetes in the future. However, the vascular risk reduction effect of statins exceeds these risks and therefore cannot be a reason to discontinue statin treatment. Patients at risk (fasting blood sugar 5.6-6.9 mmol/L, BMI > 30kg/m2, elevated triglyceride level, hypertension) should undergo clinical and laboratory monitoring according to treatment guidelines.
In the JUPITER study, the total incidence of diabetes reported in patients with fasting blood sugar levels of 5.6 to 6.9 mmol/L was 2.8% in the rosuvastatin group and 2.3% in the placebo group.
(5) Genetic polymorphism: SLCO1B1(OATP1B1) c compared to SLCO1B1 c.521TT and ABCG2 c.421CC. The genotype of 521CC or ABCG2 (BCRP) c.421AA has been reported to be associated with increased exposure (AUC) of rosuvastatin. Although the safety and effectiveness of rosuvastatin according to genetic polymorphisms have not been established, the dose needs to be adjusted according to the patient's treatment response and tolerance.
(6) Immune-mediated necrotizing myopathy: Immune-mediated necrotizing myopathy, an autoimmune myopathy related to statin use, has been reported. Immune-mediated necrotizing myopathy manifests as proximal muscle weakness and increases in blood CPK, and the symptoms persist even after discontinuation of statin administration. Additionally, muscle biopsy shows necrotizing myopathy without significant infection, and symptoms improve upon administration of immunosuppressants.
(7) Severe skin adverse reactions: Severe skin adverse reactions that can be life-threatening or fatal, such as Stevens-Johnson syndrome (SJS) and drug reaction syndrome with increased eosinophilia and systemic symptoms (DRESS), have been reported with rosuvastatin. When prescribing, patients should be advised of symptoms and signs of severe skin reactions and monitored closely. If symptoms and signs suggestive of these skin reactions occur, this medication should be discontinued immediately and alternative treatment options should be considered.
If a patient develops a severe reaction such as Stevens-Johnson syndrome or drug reaction syndrome with eosinophilia and systemic symptoms due to the use of this drug, treatment with this drug should not be resumed at any time.
(8) Severe muscle asthenia and ocular muscle atony: Rarely, statin drugs may cause or worsen severe muscle asthenia or ocular muscle atony. This drug should be used with caution in patients with these conditions. Administration should be discontinued if severe muscle atony or ocular muscle atony occurs or worsens.
6. Interaction
No pharmacokinetic drug interactions were observed in a drug interaction test conducted by administering 10 mg of amlodipine, 160 mg of valsartan, and 20 mg of rosuvastatin to healthy volunteers.
Studies on drug interactions with other drugs and amlodipine/valsartan/rosuvastatin combination were not conducted, but studies on individual drugs were conducted as follows.
1) Amlodipine
① Simvastatin: Multiple-dose co-administration of 10 mg of amlodipine and 80 mg of simvastatin increased the exposure of simvastatin by approximately 77% compared to administration of simvastatin alone. The maximum daily dose of simvastatin in patients receiving amlodipine is 20 mg.
② CYP3A4 inhibitor: When the elderly administered a combination of 5 mg of amlodipine and 180 mg of diltiazem per day, the systemic exposure of amlodipine increased by 57%. Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) may increase the blood concentration of amlodipine more than diltiazem, so amlodipine should be administered with caution when co-administered with CYP3A4 inhibitors.
③ CYP3A4 inducer: Co-administration with CYP3A4 inducer (e.g. rifampicin, St. John's wort) may change the plasma concentration of amlodipine. Therefore, blood pressure should be monitored and dose adjustments should be considered, especially during and after co-administration with strong CYP3A4 inducers.
④ Others: When amlodipine is administered alone, thiazide diuretics, alpha-blockers, beta-blockers, angiotensin converting enzyme inhibitors, long-acting nitrate preparations, nitroglycerin sublingual tablets, digoxin, warfarin, atorovastatin, sildenafil, aluminum/magnesium (antacid), cimetidine, non-steroidal drugs. It was safe when used in combination with anti-inflammatory drugs, antibiotics, oral hypoglycemic agents, ethanol (alcohol), and cyclosporine.
⑤ Grapefruit juice: When administered in combination with grapefruit juice, exposure to amlodipine may increase due to CYP3A4 inhibition. However, single oral administration of 240 mL of grapefruit juice and 10 mg of amlodipine to 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine.
⑥ Tacrolimus: When administered in combination with this drug, there is a risk of increasing the blood concentration of tacrolimus. Therefore, when administering this drug to patients being treated with tacrolimus, the blood concentration of tacrolimus should be monitored and the dosage of tacrolimus should be appropriately adjusted to avoid tacrolimus toxicity.
⑦ For additional drug interaction information, refer to the amlodipine single drug approval information.
2) Valsartan
① Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by co-administration of angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy with these drugs. In patients receiving valsartan concomitantly with other drugs that act on the RAAS, blood pressure, renal function, and electrolytes should be closely monitored. Valsartan and aliskiren-containing preparations should not be administered together to patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60 mL/min/1.73m2).
② Potassium: Caution should be exercised when using potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other drugs that may increase potassium levels (e.g. heparin), and potassium levels should be monitored frequently.
③ Non-steroidal anti-inflammatory drugs (NSAIDs): The antihypertensive effect may be reduced when angiotensin II receptor antagonists are administered simultaneously with NSAIDs (e.g., aspirin as anti-inflammatory therapy, COX-2 inhibitors). In particular, the risk of kidney function deterioration may increase in elderly patients, patients with insufficient body fluids (including patients taking diuretics), or patients with reduced kidney function. Therefore, monitoring of renal function is recommended when starting valsartan or changing the administration method in patients taking NSAIDs.
④ Lithium: A reversible increase in serum lithium concentration and toxicity has been reported with co-administration of lithium preparations and ACE inhibitors or angiotensin II receptor antagonists. Therefore, monitoring of serum lithium concentrations is recommended during coadministration. If additional thiazide diuretics are used, the risk of lithium toxicity may increase.
⑤ Transporters: In vitro studies using human liver tissue showed that valsartan is a substrate for the liver uptake transporter OATP1B1 and the liver efflux transporter MRP2. Coadministration with uptake transporter inhibitors (rifampicin, cyclosporine) or efflux transporter inhibitors (ritonavir) may increase systemic exposure of valsartan.
⑥ When valsartan was administered alone, no clinically significant drug interactions were observed with the following drugs: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, and glibenclamide.
3) Rosuvastatin
① Effects of other drugs on rosuvastatin
In vitro and in vivo studies have shown that rosuvastatin does not interact clinically with cytochrome P450 (acting as a substrate, inhibitor or inducer).
Rosuvastatin is a substrate for some transporter proteins, such as the liver uptake drug transporter OATP1B1 and the efflux transporter BCRP. When inhibitors of these transporter proteins are used together with rosuvastatin, the blood concentration of rosuvastatin increases, which may increase the risk of myopathy.
Effects of other drugs
- Antacids: When rosuvastatin was co-administered with antacids containing aluminum hydroxide and magnesium hydroxide, the plasma concentration of rosuvastatin decreased by about 50%. However, this effect was alleviated when antacids were administered 2 hours after rosuvastatin. The clinical relevance of this interaction has not been studied.
- Fusidic acid: Interaction studies between rosuvastatin and fusidic acid have not been conducted. As with other statin drugs, muscle-related adverse reactions, including rhabdomyolysis, have been reported when rosuvastatin and fusidic acid were used together in post-marketing experience. Therefore, combined use of rosuvastatin and fusidic acid is not recommended. If possible, it is recommended to temporarily discontinue rosuvastatin administration, and if administration is unavoidable, close monitoring should be performed.
② Effect of rosuvastatin on other drugs
- Warfarin: When used in combination with rosuvastatin, warfarin has no significant effect on pharmacokinetics. However, like other HMG-CoA reductase inhibitors, coadministration of rosuvastatin and warfarin may increase the INR compared to administration of warfarin alone. INR monitoring is recommended when starting, stopping, or adjusting the dose of rosuvastatin in patients receiving vitamin K antagonists (e.g., warfarin).
- Cyclosporine: Co-administration of rosuvastatin and cyclosporine does not affect the blood concentration of cyclosporine.
- Fenofibrate/fibric acid derivatives: Pharmacokinetic interactions between fenofibrate and rosuvastatin were not observed, but pharmacokinetic interactions may occur. Gemfibrozil, fenofibrate, other fibrate-based drugs, and nicotinic acid in lipid-lowering doses (more than 1 g per day) can cause myopathy when administered alone, and therefore increase the risk of myopathy when administered in combination with HMGCoA reductase inhibitors. When co-administering fibrate-type drugs, administration of 40 mg of rosuvastatin is contraindicated, and 5 mg should be administered as the initial dose.
- Oral contraceptives: When administered in combination with oral contraceptives, the AUC of ethinyl oestradiol and norgestrel increased by 26% and 34%, respectively. This increase in plasma concentration should be taken into consideration when selecting the dosage of oral contraceptives. Since there is no pharmacokinetic data for patients taking rosuvastatin and HRT together, a similar effect should not be ruled out. However, in clinical trials, the combination was administered frequently in women and the tolerability was excellent.
- Effects on other drugs: There was no clinically significant interaction with digoxin or ezetimibe.
7. Administration to pregnant and lactating women
The safety of this drug in pregnant and lactating women has not been established, so it should not be used during pregnancy or lactation.
1) Pregnant women
① Amlodipine/valsartan combination drug
Because of the mechanism of action of angiotensin II antagonists, a risk to the fetus cannot be excluded. Damage to the developing fetus and death have been reported in pregnant women taking angiotensin-converting enzyme inhibitors (a special group of drugs that act on the renin-angiotensin-aldosterone system (RAAS)) during the second and third trimesters. And the use of ACE inhibitors in the first trimester is associated with a potential risk of fetal malformations. Spontaneous abortion, oligohydramnios, and renal dysfunction in newborns have been reported in pregnant women who accidentally took valsartan. Like other drugs that act directly on the RAAS, the amlodipine/valsartan combination should not be used during pregnancy or if you plan to become pregnant. When prescribing drugs that act on RAAS to women who may become pregnant, doctors should explain the potential risks of these drugs during pregnancy. If pregnancy is confirmed during amlodipine/valsartan combination therapy, this medication should be discontinued as soon as possible.
② Rosuvastatin
The safety of rosuvastatin in pregnancy has not been established and should not be used during pregnancy.
Women of childbearing potential should use appropriate contraception. Because cholesterol and cholesterol biosynthesis products are essential for fetal development, the potential risks of inhibiting HMG-CoA reductase outweigh the benefits of treatment during pregnancy. There is evidence of limited reproductive toxicity in animal studies. If you become pregnant while using rosuvastatin, you should stop taking it immediately.
2) Nursing mothers
In animal experiments, it was confirmed that valsartan and rosuvastatin were transferred into rat breast milk, and amlodipine was reported to be transferred into human breast milk. Therefore, this drug should not be administered during breastfeeding, and nursing mothers who are inevitably taking this medication should discontinue breastfeeding.
8. Administration to children
Safety and effectiveness in pediatric patients under 18 years of age have not been established, so administration of this drug is not recommended.
9. Administration to elderly people
No dose adjustment is necessary when administering this drug to the elderly, but it should be administered with caution as it cannot be ruled out that a more sensitive reaction may occur in some elderly patients. For elderly people over 75 years of age, the clearance rate of amlodipine is reduced, so start treatment at a low dose and gradually increase the dose.
In the case of elderly people, it is generally considered undesirable to lower blood pressure excessively due to the risk of cerebral infarction, etc., so administration should be done carefully while observing the patient's condition, such as starting from a low dose. In a pharmacokinetic test on elderly people, the blood concentration of valsartan was found to be higher than that of non-elderly people.
10. Effect on clinical test values
1) Among patients with hypertension who received valsartan/amlodipine, there were very few patients whose test values clearly changed from baseline. The amlodipine/valsartan combination group (5.5%) and the valsartan alone group (5.5%) showed higher blood urea nitrogen (BUN) than the placebo group (4.5%).
2) An increase in liver function test values has occasionally been reported when administering valsartan, but special monitoring of clinical test values is not necessary for patients with essential hypertension taking this drug.
11. Treatment in case of overdose
I have no experience of overdosing on this drug. Experience with overdose of each single agent is as follows.
1) Amlodipine
Current data indicate that severe overdose may result in reflex tachycardia along with excessive peripheral vasodilation. In addition, it has been reported that symptoms of systemic hypotension are severe and persist for a long time, leading to a state of shock or resulting in fatal shock. When activated charcoal was administered to healthy volunteers immediately or up to 2 hours after administering 10 mg of amlodipine, the absorption of amlodipine was significantly reduced. In some cases, gastric lavage may be useful. Clinically serious hypotension caused by overdose of this drug requires active supportive treatment for the cardiovascular system, such as frequent monitoring of heart and respiratory function, maintaining the position of the limbs higher than the body, and ensuring sufficient circulating fluids such as blood and urine excretion. Unless there are special cases where the use of vasoconstrictors is contraindicated, vasoconstrictors may be useful in restoring vascular tone and blood pressure. Intravenous administration of calcium gluconate may be useful in reversing the effects of calcium channel inhibitors. Because amlodipine has a very high protein binding rate, hemodialysis is not helpful. Non-cardiogenic pulmonary edema has been rarely reported following amlodipine overdose. This may occur delayedly (24-48 hours after taking the dose) and may require ventilatory support. Early resuscitative measures to maintain perfusion and cardiac output (including fluid overload) may be precipitating factors.
2) Valsartan
Although there is no experience with valsartan overdose, significant hypotension, decreased consciousness, circulatory collapse and shock, tachycardia, and bradycardia due to parasympathetic nerve stimulation are expected. Immediately after taking the drug, induce vomiting or administer medicinal charcoal. Otherwise, inject physiological saline into a vein. If low blood pressure occurs, the patient should be placed in a supine position and blood volume should be corrected. Hemodialysis does not help.
3) Rosuvastatin
There is no special treatment in case of overdose. In case of overdose, symptomatic and supportive treatment should be administered. Liver function and CK levels should be monitored. Hemodialysis does not appear to help.
12. Information for professionals
1) Pharmacological action
(1) Amlodipine: It is a calcium channel blocker (CCB)-based treatment for high blood pressure. It relaxes vascular smooth muscles by blocking the calcium ion channels on the surface of myocardial and vascular smooth muscles, and increases the glomerular filtration rate by relaxing the afferent arterioles of the kidneys, thereby causing diuresis and lowering blood pressure.
(2) Valsartan: A member of the angiotensin II receptor blocker (ARB) class, it selectively and competitively antagonizes the angiotensin II receptor, a powerful vasoconstrictor, causing an increase in blood renin concentration, thereby relaxing the veins and lowering blood pressure.
(3) Rosuvastatin: 3-hydroxy-3 methylglutaryl-coenzyme A (HMG-A) reductase inhibitor. This is a drug that inhibits HMG-CoA reductase, which plays a role in catalyzing the conversion of HMG-A to mevalonate in the initial rate control stage of cholesterol biosynthesis.
2) Pharmacokinetic information
(1) One biopharmaceutical test was conducted to compare the bioavailability of this drug (amlodipine/valsartan/rosuvastatin) and the combined administration of approved drugs (amlodipine/valsartan combination and rosuvastatin single drug). A total of 48 healthy adults were administered a single dose of 10/160 mg of amlodipine/valsartan and 20 mg of rosuvastatin on an empty stomach as a three-drug combination or an approved drug (2×4 cross-over study). When the pharmacokinetic parameters were compared by measuring the blood concentrations of amlodipine, valsartan, and rosuvastatin, the 90% confidence intervals of the log-transformed mean difference of the comparative evaluation item values (AUClast, Cmax) were all within the range of bioequivalence.
(2) One comparative pharmacokinetic study was conducted to evaluate the pharmacokinetic drug interaction of amlodipine/valsartan and rosuvastatin. A total of 57 healthy adults participated and took 20 mg of rosuvastatin and 10/160 mg of amlodipine/valsartan combination alone or in combination for 17 days (2×2 crossover test). As a result of the test, no pharmacokinetic interaction was observed.
(3) Although not a test conducted with this drug, rosuvastatin increased the median AUC and Cmax approximately two-fold in Asians (Japan, China, Philippines, Vietnam, Korea) compared to Caucasians. Demographic pharmacokinetic analysis showed no clinically meaningful pharmacokinetic differences between Caucasians and blacks.
3) Clinical trial information
One randomized, double-blind, parallel group trial was conducted to comparatively evaluate the effectiveness and safety of amlodipine/valsartan/rosuvastatin combination or amlodipine/valsartan combination or valsartan/rosuvastatin combination for 8 weeks in 175 patients (Safety set) with both hypertension and dyslipidemia.
Before randomization, subjects were administered 160 mg of valsartan once a day during a therapeutic lifestyle correction period of at least 4 weeks. After the therapeutic lifestyle correction period, subjects who met the criteria according to the NCEP ATP III risk with an average systolic blood pressure of more than 140 mmHg but less than 180 mmHg, TG less than 400 mg/dL, and LDL-C were eligible for this drug (amlodipine/valsartan). Patients were randomly assigned to receive 10/160 mg and rosuvastatin 20 mg), amlodipine/valsartan 10/160 mg, or valsartan and rosuvastatin 160/20 mg.
As co-primary efficacy endpoints, the change in msSBP of this drug compared to the valsartan and rosuvastatin group and the LDL-C change rate (%) of this drug compared to the amlodipine/valsartan group were evaluated.
When an analysis of covariance (ANCOVA) was performed on the primary efficacy endpoints, the amount of change in msSBP and the rate of change in LDL-C levels compared to the baseline, with the mean value of the baseline adjusted as a covariate, the change in msSBP and the rate of change in LDL-C in the test group were superior to those in the respective control groups (p<0.0001).
4) Toxicity test information
(1) Repeated dose toxicity
A repeated dose toxicity test was conducted in rats in which the test substances (amlodipine/valsartan/rosuvastatin) were orally administered for 13 weeks, and no new unknown toxicological changes were observed in each single ingredient.
(2) Reproductive and developmental toxicity
Although additional reproductive and developmental toxicity tests were not conducted for the development of combination drugs, the known reproductive and developmental toxicity for each single drug is as follows.
① Amlodipine
Other than delayed and prolonged parturition in rats administered amlodipine at a dose equivalent to 50 times the maximum recommended dose for humans, no reproductive toxicity has been proven in animals.
② Valsartan
A decreased survival rate and a slight delay in physical development were observed in the offspring of rats administered 600 mg/kg/day during the last 3 months of pregnancy and lactation.
In a rat fertility test, it was observed that oral administration up to 200 mg/kg/day, which is approximately 6 times the maximum recommended dose (MRHD) for humans based on body surface area (mg/m2), did not affect the fertility of male or female rats.
In embryo-fetal development tests on mice, rats, and rabbits, fetal toxicity associated with maternal toxicity was observed in rats administered 600 mg/kg/day and rabbits administered 10 mg/kg/day. These doses are 18 and 0.6 times the maximum recommended human dose, respectively, based on body surface area (mg/m2) (assuming an oral dose of 320 mg/day for a 60 kg patient). There was no evidence of maternal or fetal toxicity in mice dosed up to 600 mg/kg/day, which is 9 times the maximum recommended human dose based on body surface area (mg/m2).
③ Rosuvastatin
In prenatal and postnatal developmental tests in rats, reproductive toxicity was observed, including reduced litter size, reduced litter weight, and reduced survival of the next generation. This effect was observed when a dose equivalent to several times the therapeutic dose was administered systemically to the mother.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 8items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 8 | Valtrio tab 10/160/10mg | Precautions for use | 2026.08.21 | PDF202006710_Baltriojeong10_160_10.pdf |
| 7 | Valtrio tab 10/160/10mg | Precautions for use | 2026.04.07 | PDF202006710_Valtrio Tablet 10/160/10mg_Precautions for use (draft).pdf |
| 6 | Valtrio tab 10/160/10mg | Precautions for use | 2026.02.12 | PDF0506_202006710_Precautions for use_Valtriol 10/160/10mg.pdf |
| 5 | Valtrio tab 10/160/10mg | Precautions for use | 2026.02.12 | PDF0444_202006710_Precautions for use_Valtriol 10/160/10mg.pdf |
| 4 | Valtrio tab 10/160/10mg | Precautions for use | 2024.08.30 | PDFValtrio Tablet 10│160│10mg_Precautions for use.pdf |
| 3 | Valtrio tab 10/160/10mg | Precautions for use | 2024.04.23 | PDFValtriol 10│160│10mg_Permission change order (draft) (precautions for use).pdf |
| 2 | Valtrio tab 10/160/10mg | Precautions for use | 2023.04.06 | PDF0834_202006710_Precautions for use_Valtriol 10/160/10mg (including change comparison table).pdf |
| 1 | Valtrio tab 10/160/10mg | Precautions for use | 2022.01.25 | PDFPrecautions for use of Valtrio Tablet.pdf |